U of C research could help doctors prevent acute kidney injury
New University of Calgary research could give doctors a therapeutic to prevent acute kidney injury in high-risk patients.
Stay updated with breaking news from Dan Muruve. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New University of Calgary research could give doctors a therapeutic to prevent acute kidney injury in high-risk patients.
New University of Calgary research could give doctors a therapeutic to prevent acute kidney injury in high-risk patients.
Being part of the national trial means data will soon be available that can determine whether Metablok is a viable treatment for COVID-19.
Watch this page throughout the day for updates on COVID-19 in Calgary.
Author of the article: Jason Herring Publishing date: Feb 13, 2021 • February 13, 2021 • 3 minute read • Dr. Dan Muruve (left), chief science officer of Arch Biopartners, and Dr. Alain Tremblay, professor at the University of Calgary's Cumming School of Medicine, are facilitating a Phase II human trial in Calgary for Metablok, a drug developed to combat organ inflammation often in severe cases of COVID-19. Photo by Submited Article content A made-in-Calgary drug that researchers hope can treat organ inflammation is now being tested on local COVID-19 patients. The Univer...